The term immunoconglutinin designates antibody specifically reactive against the normally hidden antigenic determinants of C'3 complement which are exposed when it combines with immune complexes (Lachmann and Coombs, 1965) . The presence of immunoconglutinin in serum therefore specifically indicates previous humoral immunological activity, and the magnitude of both phenomena show a direct relationship. Depression of serum C'3 complement may indicate such activity as wel!, but is less specific since its level may also be affected in either dii-ection by such non-immunological factors as variation in production and catabolism, or urinary loss. Fuithermore, the immunoconglutinin response to an episode of humoral immunological activity persists for some time, so that its detection is less temporally limited than the relatively transient depression of complement level (Coombs, Coombs, and Ingram, 1961) . Loeschke (1927) originally suggested that amyloid substance might represent tissue deposits of antigenantibody complexes, and Strukov, Serov, and Pavlikhina (1963) have offered evidence which seems to show that autoantibodies to the deposits develop during the course of human and animal amyloidosis. The idea that amyloid substance could be at least partly constructed immunologically may be considered to gain moment from demonstrations by the fluorescent antibody technique of the presence in, or binding by, amyloid of C'3 complement (Kochem, 1966; Lachmann, Muller-Eberhard, Kunkel, and Paronetto, 1962; Letterer, Caesar, and Vogt, 1960;  Muller-Eberhard and Dalmasso, 1965; Nowoslawski and Brzosko, 1965; Vogt and Kochem, 1960) .
If antigen-antibody reactions in vivo do play any part in the development of amyloidosis, an elevation in serum immunoconglutinin should be evident at some stage in the disease. In actively progressive amyloidosis such elevations might be expected to be c 5 nearly continuous and so almost certainly detectable at any time during its course. Absence of immunoconglutinin elevation in amyloidosis may be taken as evidence either of lack of importance of immunological reactions in the development of the disease, or of incapacity to produce specific antibody to immunologically-bound complement.
In this study, immunoconglutinin levels were estimated in 37 sera from 27 patients with amyloidosis, including three with concomitant myelomatosis; 21 sera from nineteen patients with myelomatosis alone; and one hundred sera from normal subjects.
Method
The technique of estimating serum immunoconglutinin level used was that described by Coombs and others (1961) , Method Ilb, in which serial dilutions of the test sera in dilute inactivated horse serum are examined for their ability to agglutinate sheep red cells alexinated by exposure to a suitable natural bovine Forssman antibody followed by horse complement. Controls included in each run comprised:
(1) A known negative serum and one of known positive titre.
(2) The alexinated cells alone to exclude artefactual agglutination.
(3) A 1: 2 dilution of the test serum with the cell system containing 56°C. inactivated instead of active horse complement to indicate any irrelevant human antibodies against horse or bovine serum proteins, or incomplete absorption with the red cells.
All sera were examined in duplicate, usually on more than one occasion. If the titre varied in a duplicate by more than one tube, an aliquot of that serum specimen was re-examined upon at least one other occasion.
Material
Sheep blood was collected into one fifth volume of standard solution of acid-citrate-dextrose. Horse sera as a source of conglutinating complement, and bovine sera for the natural Forssman antibody to sheep red i31 cells, were obtained by whipping defibrination of blood, the clots being left in contact with the sera for 6 hours at room temperature to allow completion of the coagulation process.
The technique of immunoconglutinin estimation was practised for several weeks before any of the test sera were examined. Early during this practice period it became apparent that individual sheep, cows, and horses showed considerable variation in the desirable qualities of their respective contributing materials. A number of horse and bovine sera were therefore screened in individual cross-combinations, and the pair giving the most clear-cut conglutination, end-point, and negative with known negative and positive sera were stored at -35°C. in aliquot volumes sufficient for a day's tests. Each aliquot was thawed once, on the day of test, and any remaining was discarded. Heat inactivation, absorption, and other manipulations were carried out after thawing on the day of test. Each new lot of sheep red cells was checked before use with sera of known positive titre, and a known negative.
Human blood specimens were collected by venepuncture and allowed to clot at 37°C. for 4 hours. The sera were separated by centrifugation, and each sample was stored in several aliquots at -35°C. until required. The period of such storage varied from one week to nearly 4 years; it had already been established that antibody was stable under these conditions for at least 5 years.
All cases of amyloidosis were proven by biopsy or subsequent autopsy. Criteria for the diagnosis of myelomatosis were paraprotein production in great excess with notable diminution of other immunoglobulins as determined by immunoelectrophoresis, and characteristic bone marrow changes.
Results Details of the patients, their diseases, and immunoconglutinin titres are given in Table I (opposite). The incidence of the titres in normal and affected groups is given along with the statistics of Coombs and others (1961) in Table IT, and in Statistical analysis by x2 tests showed that the range and frequency of immunoconglutinin titres found in normal persons in this study were essentially the same as the normal values given by Coombs and others (1961) .
The amyloid group sera titres were significantly raised (P= <005 but >001), but this difference was due to minor elevations and no titre higher than 1: 8 was found. The values found for the patients with myelomatosis also showed departure from normal, but the level of significance was low (P= < 0 -1 but > 0 05), and there was no apparent correlation of the titres with the presence or absence of associated amyloidosis.
Discussion
These results show that patients with amyloidosis tend to have slightly higher immunoconglutinin titres than normal, and might appear to support the concept of an immunological basis for amyloidosis. However, the difference is due mainly to minor rises in patients who had predisposing chronic inflammation and who, from previous reports The three patients with both diseases were included for this purpose in both groups. xI tests showed that the two groups of normal subjects did not differ and that the significance of the deviation from normal shown by tshe diseased groups was as follows:
Amyloid P-<005 but >0 01. Myeloma P=<0 l but >005. (Coombs and others, 1961; Caspary and Ball, 1962; Percy, 1966) , would actually have been expected to show very much higher levels. Experimental amyloidosis may be associated with immunological incapacity (Muckle, 1968) and it seems possible that these patients with chronic inflammation and amyloidosis had in some measure lost the ability to mount a specific immune response to in-vivo bound C'3 complement. So far as the activity and severity of amyloidosis could be assessed during the patients' lives, there was an impression of some association between unexpectedly low or negative immunoconglutinin levels and progressive or advanced amyloid disease.
Thus, the sera of two patients contained no activity although both had had extensive active chronic suppuration present for some time. Case 2 had grossly purulent massive bronchiectasis with advanced amyloidosis. Case 6 (Jan. 1965) with presumably early but actively progressive amyloid disease since proteinuria (11 g./day) had appeared for the first time 3 weeks before and rectal biopsy showed only moderate deposits of amyloid, had numerous profusely suppurating perineal sinuses.
Furthermore, four other patients with active sepsis (Case 1, 3, 4, and 5) and three patients with active rheumatoid arthritis (Cases 15, 16, and 18), all with advanced and presumably progressive amyloidosis, showed no or only slightly raised immunoconglutinin levels in their sera. That these patients did not exhibit very high immunoconglutinin titres accompanying such active inflammatory diseases is remarkable in view of the findings of Coombs and others (1961) , Caspary and Ball (1962) , and Percy (1966) in similar cases without amyloidosis.
Nevertheless, although very suggestive, these few examples can hardly be accepted as conclusive. Certainly, amyloidosis is not always accompanied by complete immunological incompetence towards bound C'3 complement, since several patients did show some immunoconglutinin activity in their sera. The most that can be ventured is that low immunoconglutinin titres in patients with active rheumatoid arthritis or active chronic massive sepsis may indicate the presence of amyloidosis. The connecting links are immunological incompetence towards the agent or organism causing the inflammation, with consequently diminished humoral immune reaction and immunological C'3 complement binding which, in turn, affords only weak stimulation to an impaired ability for immunoconglutinin response. If real, this association could provide a useful diagnostic tool, but its evaluation will require study of a much larger series of patients.
In view of this consideration of immunological incompetence, it will be apparent that the absence of notable immunoconglutinin elevations in these patients with amyloidosis cannot be accepted as excluding the possibility that immunological activity is involved in the development of the disease or formation of amyloid substance. However, it may be deemed unlikely that immune reactions would make any important contribution in the presence of sipificant immunological incompetence. Serum C'3 complement levels were found to be normal in twenty cases of primary and secondary amyloidosis (Ellis and Walton, 1958; Williams and Law, 1960) , and in ten cases of myelomatosis and lymphomata without amyloidosis (Williams and Law, 1960) , so that it would perhaps have been surprising to find that immunoconglutinin levels were unusually raised in such cases. However, Williams and Law (1960) found low or nonexistent serum C'3 complement levels in seven examples of myelomatosis complicated by amyloidosis, raising the possibility that increased consumption of complement might be involved in this particular form of amyloid disease. The authors considered that this was not likely to be immunological in nature since they found no anticomplementary activity in the sera, and the present finding of ao high immunoconglutinin titres in the sera of three such subjects supports their conclusion.
The patients with myelomatosis also seemed to show an inverse relationship between the immunoconglutinin titres and the severity of their condition, and a degree of immunological inadequacy may accompany this disease. However, in view of the small number of patients studied, lack of specific tests of immunological competence, or accurate assessment of the severity of the myelomatosis by paraprotein quantitation, valid conclusions cannot be drawn on this point.
Summary
Immunoconglutinin levels were estimated in random samples of serum from patients with various forms of amyloidosis, with myelomatosis, and with both diseases, and from normal persons. Elevations of statistical significance but of minor degree were found, particularly in the group of amyloid patients. In a number of these the elevations were very much less than would have been expected from the nature of their predisposing conditions, which suggested some associated loss of immunological competence. The results do not support the concept of an immunological basis for the formation of amyloid deposits but, because of the latter indication, cannot be considered as exclusive of this possibility. 
